C4 Therapeutics, Inc. (CCCC) Misses Q2 EPS by 1c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.73), $0.01 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $5.39 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns
• Target raises full-year sales forecast amid ongoing turnaround drive